{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Muniyan S"],"funding":["NIDDK NIH HHS","NHLBI NIH HHS","NCI NIH HHS","NIH","Department of Defense"],"pagination":["5720-5734"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7642013"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["26(21)"],"pubmed_abstract":["<h4>Purpose</h4>Docetaxel plays an indispensable role in the management of advanced prostate cancer. However, more than half of patients do not respond to docetaxel, and those good responders frequently experience significant cumulative toxicity, which limits its dose duration and intensity. Hence, a second agent that could increase the initial efficacy of docetaxel and maintain tolerability at biologically effective doses may improve outcomes for patients.<h4>Experimental design</h4>We determined phosphodiesterase 5 (PDE5) expression levels in human and genetically engineered mouse (GEM) prostate tissues and tumor-derived cell lines. Furthermore, we investigated the therapeutic benefits and underlying mechanism of PDE5 inhibitor sildenafil in combination with docetaxel using <i>in vitro</"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["Sildenafil Potentiates the Therapeutic Efficacy of Docetaxel in Advanced Prostate Cancer by Stimulating NO-cGMP Signaling."],"pmcid":["PMC7642013"],"funding_grant_id":["R01 DK120866","W81XWH-18-1-0308","PC170891","HL118808","R01 HL118808","R01 HL134366","R01 CA221813","U01 CA185148","DK120866"],"pubmed_authors":["Rauth S","Islam R","Rachagani S","Muniyan S","Datta K","Vengoji R","Mallya K","Kukreja RC","Parte S","Kshirsagar P","Teply BA","Xi L","Seshacharyulu P","Das A","Batra SK","Halder S","Siddiqui JA"],"additional_accession":[]},"is_claimable":false,"name":"Sildenafil Potentiates the Therapeutic Efficacy of Docetaxel in Advanced Prostate Cancer by Stimulating NO-cGMP Signaling.","description":"<h4>Purpose</h4>Docetaxel plays an indispensable role in the management of advanced prostate cancer. However, more than half of patients do not respond to docetaxel, and those good responders frequently experience significant cumulative toxicity, which limits its dose duration and intensity. Hence, a second agent that could increase the initial efficacy of docetaxel and maintain tolerability at biologically effective doses may improve outcomes for patients.<h4>Experimental design</h4>We determined phosphodiesterase 5 (PDE5) expression levels in human and genetically engineered mouse (GEM) prostate tissues and tumor-derived cell lines. Furthermore, we investigated the therapeutic benefits and underlying mechanism of PDE5 inhibitor sildenafil in combination with docetaxel using <i>in vitro</","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Nov","modification":"2025-04-04T01:45:33.245Z","creation":"2022-02-09T18:08:48.86Z"},"accession":"S-EPMC7642013","cross_references":{"pubmed":["32847934"],"doi":["10.1158/1078-0432.CCR-20-1569","10.1158/1078-0432.ccr-20-1569"]}}